Vaxart, Inc.
http://www.vaxart.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vaxart, Inc.
Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery
Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.
Finance Watch: Ferring Shutters San Diego R&D Site As Even Money-Making Firms Cut Costs
Restructuring Edition: After reporting record revenue, but lower profits due to rising costs, Ferring has decided to consolidate R&D in Europe. Also, Codiak has filed for Chapter 11 bankruptcy and will sell off its assets, while Exicure, Applied Molecular Transport, Gamida Cell and others revealed new job cuts.
Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
Takeda Takes Alliance Route For Norovirus Vaccine
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Vaccines
- Other Names / Subsidiaries
-
- Aviragen Therapeutics, Inc. (Anaconda Pharma SAS
- Biota Holdings Limited
- Biota Pharmaceuticals, Inc.
- Nabi Biopharmaceuticals)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice